Nasdaq · Healthcare
ARDELYX, INC. (ARDX)
As-reported financials and recent SEC filings for ARDELYX, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$407.3M
Net income
$-61.6M
Net margin
-15.1%
Diluted EPS
$-0.26
ROE
-36.9%
P/E (TTM)
—
Market cap
$1.37B
Debt / equity
1.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $407.3M | $333.6M | $124.5M | $52.2M | $10.1M |
| Gross profit | $367.8M | $283.1M | $106.7M | — | $9.1M |
| Operating income | $-41.0M | $-27.9M | $-63.3M | $-63.8M | $-154.3M |
| Net income | $-61.6M | $-39.1M | $-66.1M | $-67.2M | $-158.2M |
| Diluted EPS | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →Go deeper on ARDX
Search ARDELYX, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.